trisequens has been researched along with medroxyprogesterone acetate in 3 studies
| Studies (trisequens) | Trials (trisequens) | Recent Studies (post-2010) (trisequens) | Studies (medroxyprogesterone acetate) | Trials (medroxyprogesterone acetate) | Recent Studies (post-2010) (medroxyprogesterone acetate) |
|---|---|---|---|---|---|
| 56 | 35 | 1 | 5,123 | 1,115 | 1,099 |
| Protein | Taxonomy | trisequens (IC50) | medroxyprogesterone acetate (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 0.924 | |
| Glucocorticoid receptor | Homo sapiens (human) | 0.013 | |
| Progesterone receptor | Homo sapiens (human) | 2.5081 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.019 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 1.197 | |
| Androgen receptor | Homo sapiens (human) | 0.0061 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.279 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.019 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.019 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.019 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.197 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 1.4059 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 4.0405 | |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | 1.8 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.924 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamant, YZ; Kleinman, Y; Livshin, Y; Reisin, A; Tadmor, OP | 1 |
| Bilgen, I; Bilgin, O; Coşan Terek, M; Memiş, A; Ozşener, S; Oztekin, K; Sendağ, F | 1 |
| Andersen, TO; Eilertsen, AL; Høibraaten, E; Os, I; Sandset, PM; Sandvik, L | 1 |
1 trial(s) available for trisequens and medroxyprogesterone acetate
| Article | Year |
|---|---|
The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
Topics: Administration, Cutaneous; Administration, Oral; Blood Coagulation; C-Reactive Protein; Drug Combinations; Estradiol; Estriol; Female; Hormone Replacement Therapy; Humans; Interleukin-6; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; P-Selectin; Risk Factors; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Venous Thrombosis | 2005 |
2 other study(ies) available for trisequens and medroxyprogesterone acetate
| Article | Year |
|---|---|
The effects of two fixed hormonal replacement therapy protocols on blood lipid profile.
Topics: Clinical Protocols; Drug Combinations; Estradiol; Estriol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Lipids; Medroxyprogesterone Acetate; Menopause; Middle Aged; Norethindrone; Prospective Studies | 1992 |
Mammographic density changes during different postmenopausal hormone replacement therapies.
Topics: Cyproterone Acetate; Drug Combinations; Estradiol; Estriol; Estrogen Replacement Therapy; Estrogens; Female; Humans; Mammography; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Norethindrone Acetate; Norpregnenes; Postmenopause; Progesterone Congeners; Retrospective Studies; Time Factors | 2001 |